Hépato-Gastro & Oncologie Digestive
MENUTargeted therapies and chemotherapy-related colitis: diagnosis and management of different entities Volume 22, issue 6, Juin 2015
Authors
1 Hôpital Cochin,
service de gastro-entérologie,
27 rue du Faubourg Saint Jacques,
75014 Paris, France
service de gastro-entérologie,
27 rue du Faubourg Saint Jacques,
75014 Paris, France
* Tirés à part
- Key words: chemotherapy, targeted therapy, ischemic colitis, neutropenic colitis, Clostridium difficile, immuno-mediated colitis
- DOI : 10.1684/hpg.2015.1165
- Page(s) : 500-5
- Published in: 2015
Systemic anticancer drugs (cytotoxic compounds and targeted therapies) frequently induce gastrointestinal adverse effects (nausea, vomiting, diarrhea), treated by symptomatic measures. These symptoms can also reveal the occurrence of colitis, a less frequent but more severe complication which requires an early diagnosis, and an optimal and multidisciplinary management. Several entities are distinguished: Clostridium Difficile infectious colitis, neutropenic colitis, or ischemic colitis. Targeted therapies may also damage digestive mucosal, leading to colitis. Ipilimumab-related colitis is the most described, but others agents can be implied. Characteristics of these different entities will be developed in this review.